Receptors also modulate response to therapy [8,9], we also assessed, as a secondary aim of this study, the predictive value of DC-SCRIPT by using clinical benefit and progression-free survival (PFS) after first-line tamoxifen for advanced disease as the main endpoints.Materials and methodsPatientsdetermined by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) [14,16,17]. Follow-up
The Reporting Recommendations for Tumor Marker Prognostic Studies guidelines [11]. The primary breast tumors were from patients with detailed clinical follow-up as previously described [12-14]. ER protein status was determined by routine ligand-binding assays or enzyme immunoassays [15], and ESR1, ESR2, and PGR mRNA status wasTissue processing, RNA isolation, cDNA synthesis, and quantitative RT-PC